Isunakinra

Isunakinra
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	1422950-20-5
PubChem	91873360
DrugBank
ChemSpider
KEGG

Isunakinra (also known by its development code EBI-005) is a recombinant protein that acts as an interleukin-1 receptor antagonist. It is being investigated for its potential use in treating inflammatory conditions, particularly those affecting the eyes and skin.

Mechanism of Action

Isunakinra functions by inhibiting the activity of interleukin-1 (IL-1), a cytokine that plays a key role in the inflammatory response. By blocking the IL-1 receptor, isunakinra prevents the downstream signaling that leads to inflammation and tissue damage. This mechanism is similar to that of anakinra, another IL-1 receptor antagonist, but isunakinra is engineered to have properties that may be more suitable for topical applications.

Clinical Development

Isunakinra has been primarily investigated for the treatment of dry eye disease and allergic conjunctivitis. These conditions are characterized by inflammation of the ocular surface, where IL-1 is thought to be a significant contributor to the pathophysiology.

Dry Eye Disease

In clinical trials, isunakinra has been evaluated for its efficacy in reducing the symptoms of dry eye disease, such as ocular discomfort and visual disturbance. The trials have focused on its ability to improve tear production and reduce inflammation on the ocular surface.

Allergic Conjunctivitis

For allergic conjunctivitis, isunakinra is being studied for its potential to alleviate symptoms such as itching, redness, and swelling of the eyes. The anti-inflammatory properties of isunakinra may help in reducing the allergic response mediated by IL-1.

Safety and Efficacy

The safety profile of isunakinra has been assessed in several clinical trials. Common side effects reported include mild irritation at the site of application. The efficacy results have shown promise, but further studies are needed to confirm its benefits and establish optimal dosing regimens.

Regulatory Status

As of the latest updates, isunakinra is still under investigation and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Also see

• Interleukin-1 receptor antagonist
• Anakinra
• Dry eye syndrome
• Allergic conjunctivitis

Receptor Antagonists
Receptor Type	Example Antagonists
Adrenergic receptor	Propranolol, Prazosin
Cholinergic receptor	Atropine, Scopolamine
Dopamine receptor	Haloperidol, Clozapine
Histamine receptor	Ranitidine, Diphenhydramine
Serotonin receptor	Ondansetron, Risperidone
Glutamate receptor	Memantine, Ketamine
GABA receptor	Flumazenil, Bicuculline
Opioid receptor	Naloxone, Naltrexone
Angiotensin receptor	Losartan, Valsartan